hengrui – Lab DB

Pharmaceutical R&D

Bristol Myers Squibb and Hengrui Pharma Forge Landmark $15.2 Billion Oncology and Immunology Collaboration

Teuku Ryan May 13, 2026 0

Bristol Myers Squibb (BMS) and Chinese biopharmaceutical giant Hengrui Pharma have announced a monumental licensing and collaboration agreement, potentially valued…

Bristol Myers Squibb and Hengrui Pharma Forge Landmark $15.2 Billion Oncology and Immunology Collaboration

YOU MAY HAVE MISSED

World-first gene editing application unveils master regulator of human embryo development

Navigating the Knowledge Gap: How Workforce Shifts and Advanced Therapies Threaten Biopharma’s Critical Tech Transfer Process

Anixa Biosciences Secures Key Patent for Breast Cancer Vaccine Technology in South Korea, Expanding Global Intellectual Property Portfolio

An abundance of food may trigger this microbe’s strange transformation